A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Adult Patients With Moderate and Severe Atopic Dermatitis

A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis

Inclusion Criteria:

• Have fully understood the test and voluntarily signed the informed consent;
• When signing the informed consent form, the age of male or female subjects must be ≥ 18 years old;
• The onset time of atopic dermatitis was at least 1 year at the time of screening, and the subjects met the Hanifin and Rajka criteria for atopic dermatitis at the time of screening;
• For women with reproductive ability and all male subjects, during the trial period and within 6 months after the discontinuation of the trial drug, they must maintain abstinence or contraception, including but not limited to physical and drug contraception.
• The subjects were able to communicate well and agreed to follow the study and follow-up procedures.

Exclusion Criteria:

• The investigator considers that any subjects are not suitable to participate in the trial.